01—Abstract
Summary
Summary of the 10-Q filed July 27, 2021. Cited figures are marked; the original filing is the authoritative source.
Philip Morris International Inc. (PM) reported strong financial results for the six months ended June 30, 2021.
Net revenues increased by 10.0% year-over-year to $15.2 billiona, driven by a 39.1% surge in Reduced-Risk Products (RRPs) revenue, which reached $4.4 billion, and a modest 1.3% increase in combustible product net revenues. Diluted Earnings Per Share (EPS) grew by 21.1% to $2.93, reflecting operational improvements, favorable currency movements, and the positive impact of tax rate changes, partially offset by asset impairment charges and a significant Saudi Arabia customs assessment. The company's strategic shift towards smoke-free products continues to gain traction, with RRPs showing substantial growth across key markets like the EU and East Asia & Australia.
Despite challenges such as a $246 millionb impact from Saudi Arabia customs assessments and ongoing restructuring costs, PMI demonstrated robust operational performance. The company also announced significant acquisitions in the pipeline, Vectura and Fertin Pharma, signaling a strategic expansion into adjacent health-related industries. PMI's balance sheet remains strong, with ample liquidity from its credit facilities and a new $7 billion share repurchase program authorized.
02—Key points
Key Highlights
- Net revenues increased by 10.0% to $15.2 billion for the six months ended June 30, 2021, driven by strong growth in Reduced-Risk Products (RRPs).
- Diluted EPS increased by 21.1% to $2.93 for the six months ended June 30, 2021, demonstrating improved profitability.
- Reduced-Risk Products (RRPs) net revenues grew by 39.1% to $4.4 billion, highlighting the success of PMI's smoke-free transition strategy.
- Favorable currency movements contributed positively to both net revenues and diluted EPS.
- A significant unfavorable impact of $246 million was recorded from Saudi Arabia customs assessments, affecting net revenues and operating income.
- Asset impairment and exit costs were incurred primarily due to organizational design optimization and South Korea distribution restructuring.
- The company announced significant strategic acquisitions of Vectura Group plc and Fertin Pharma A/S to expand into health-related industries.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2021, Philip Morris International Inc. kept $0.29.
- Revenue$7.59B100.0%
- Cost of revenue−$2.35B31.0%
- Gross profit$5.24B69.0%
- Operating costs−$2.11B27.8%
- Operating income$3.13B41.2%
- Interest, other & tax−$957.0M12.6%
- Net income$2.17B28.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2021filed July 27, 2021Financial Statements
Q2 FY2021 against Q2 FY2020
| Line item | Q2 FY2021Q2 FY2020 | Change |
|---|---|---|
| Revenue | $7.59B$6.65B | +14.2% |
| Cost of Revenue | $2.35B$2.18B | +8.0% |
| Gross Profit | $5.24B$4.47B | +17.2% |
| Operating Income | $3.13B$2.73B | +14.6% |
| Net Income | $2.17B$1.95B | +11.6% |
| EPS (Basic) | $1.39$1.25 | +11.2% |
| EPS (Diluted) | $1.39$1.25 | +11.2% |
| Shares Outstanding (Basic) | 1.56B1.56B | 0.0% |
| Shares Outstanding (Diluted) | 1.56B1.56B | +0.1% |
05—Questions
Frequently Asked Questions
What was the primary driver of Philip Morris International's revenue growth in the first half of 2021?
The primary driver of Philip Morris International's revenue growth was the strong performance of its Reduced-Risk Products (RRPs), which saw a 39.1% increase in net revenues, alongside a modest increase in combustible product net revenues and favorable currency movements.
What impact did the Saudi Arabia customs assessments have on the company's financial results?
The Saudi Arabia customs assessments resulted in a $246 million reduction in net revenues and negatively impacted operating income and diluted EPS by $0.14 per share in the second quarter of 2021, due to unfavorable appeals decisions regarding distributor assessments.
How is Philip Morris International progressing with its smoke-free product strategy?
Philip Morris International is making significant progress with its smoke-free product strategy, as evidenced by the substantial 39.1% year-over-year growth in net revenues from Reduced-Risk Products (RRPs). This growth is being driven by strong performance in key markets like the EU and East Asia & Australia, indicating a successful transition towards smoke-free alternatives.
What are the implications of the Vectura and Fertin Pharma acquisitions for PMI?
The proposed acquisitions of Vectura and Fertin Pharma represent a strategic diversification for Philip Morris International, expanding its presence into adjacent health-related industries focused on inhaled drug delivery and oral delivery systems. These acquisitions are expected to contribute to the company's transformation beyond traditional tobacco products.
06—Continue